Περίληψη:
Disease-modifying treatment strategies for Alzheimer disease (AD) are
still under extensive research. Nowadays, only symptomatic treatments
exist for this disease, all trying to counterbalance the
neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine.
To block the progression of the disease, therapeutic agents are supposed
to interfere with the pathogenic steps responsible for the clinical
symptoms, classically including the deposition of extracellular amyloid
beta plaques and intracellular neurofibrillary tangle formation. Other
underlying mechanisms are targeted by neuroprotective,
anti-inflammatory, growth factor promotive, metabolic efficacious agents
and stem cell therapies. Recent therapies have integrated multiple new
features such as novel biomarkers, new neuropsychological outcomes,
enrollment of earlier populations in the course of the disease, and
innovative trial designs. In the near future different specific agents
for every patient might be used in a “precision medicine” context,
where aberrant biomarkers accompanied with a particular pattern of
neuropsychological and neuroimaging findings could determine a specific
treatment regimen within a customized therapeutic framework. In this
review, we discuss potential disease-modifying therapies that are
currently being studied and potential individualized therapeutic
frameworks that can be proved beneficial for patients with AD.
